Core Viewpoint - The article discusses the recovery of valuations in the offline consumption sector driven by store expansion logic, with public funds heavily investing in leading chain consumption stocks showing strong price performance [1]. Group 1: Store Expansion and Investment Logic - Store expansion has become a key selection criterion for public funds in identifying investment opportunities in consumer stocks, closely linked to the prevailing investment sentiment in the market [2][3]. - The number of stores is a crucial anchor in the valuation model for consumer stocks, reflecting the strength of the market segment; companies that shrink their store networks are often viewed negatively by public funds [3]. - The chain pharmacy industry exemplifies the pressure on valuations due to store closures, with predictions of approximately 39,000 offline pharmacies closing in 2024, leading to long-term underperformance of several heavily invested stocks [3]. Group 2: Performance of Leading Consumer Stocks - Leading consumer stocks such as Nayuki Tea and Daphne have mirrored the cycles of store expansion and contraction, suffering significant declines in performance following store closures [4]. - Nayuki Tea closed 132 stores in the first half of 2025, resulting in a market value drop to below HKD 2.5 billion; Daphne has been abandoned by public funds after a significant reduction in its store count [4]. - The expansion of stores is seen as a critical support for price elasticity in consumer companies, enhancing brand exposure and market penetration, which in turn drives revenue growth [4]. Group 3: Successful Cases of Store Expansion - Beauty SPA chain Meili Tianyuan Health has shown strong store expansion momentum, reaching 734 stores across 20 cities, with projected revenues of at least RMB 3 billion and adjusted net profits of at least RMB 380 million for 2025, reflecting a growth rate of no less than 40% [5]. - Dashi Co., the first listed pizza chain in China, reported a total of 1,315 stores by the end of 2025, with a net increase of 307 stores in the fourth quarter alone [6]. - Other consumer stocks like Langzi Co., Li Ning, and Guoquan have also aligned with the growth logic driven by store expansion, with Langzi Co. projecting a net profit of RMB 900 million to 1.05 billion for 2025, a year-on-year increase of 245.25% to 302.8% [6]. Group 4: Optimism for Future Investment - Public fund managers are optimistic about investment opportunities in the consumer sector for 2026, particularly in optional and new consumption segments, with a notable increase in focus on these areas [8]. - The investment value of the consumer sector is gradually becoming apparent, especially in optional consumption areas that have shown signs of recovery by the end of 2025 [8]. - Fund managers are shifting their investment focus towards "new consumption" and "gaming" sectors, emphasizing brands that resonate with Generation Z and have potential for innovation and market expansion [8].

Core Viewpoint - Longzi Co., Ltd. expects a significant increase in net profit attributable to shareholders for 2025, projecting a profit range of 900 million to 1.05 billion yuan, representing a year-on-year increase of 245.25% to 302.80% compared to the adjusted profit of 260.68 million yuan from the previous year [1] Financial Performance - The projected net profit for 2025 is estimated to be between 900 million yuan and 1.05 billion yuan [1] - This represents a substantial increase of 245.25% to 302.80% compared to the adjusted profit of 260.68 million yuan from the previous year [1]

智通财经APP讯，朗姿股份(002612.SZ)披露2025年年度业绩预告，公司预计归属于上市公司股东的净利 润9亿元至10.5亿元，同比增长245.25%至302.80%。扣除非经常性损益后的净利润2.2亿元至2.9亿元，同 比增长1.09%至33.25%。 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 出品：新浪财经上市公司研究院 作者：新消费主张/cici 然而，医美诊疗服务的营收增长多是以"破价"、低基数换来的，"低价"是新氧自营诊所快速打开市场的 核心武器，但这一策略本身也暗含多重风险对公司持续盈利能力构成较大威胁。除此之外，新氧低价策 略直接击穿了上游厂商苦心维护的价格体系，已导致其与多家主流供应商关系破裂，被部分厂商列 入"非官方合作"名单、甚至被部分厂商断供。 核心业务持续低迷信息与预订服务Q3收入-34.5% 多次转型反拖累业绩、医美诊疗服务挑大梁？ 2019年5月，新氧于纳斯达克上市，成为互联网医美服务平台第一股。近年来，受行业竞争加剧、医美 机构付费意愿下降等因素影响，新氧的业绩表现难言乐观。2024年，新氧业绩双降，共实现营收14.67 亿元，同比下降2.1%；归母净亏损却高达5.87亿元，创近四年亏损新高。这一数据背后，是核心业务萎 缩、转型成本激增与历史投资暴雷的三重绞杀。 首先，核心业务萎缩，即新氧赖以起家的信息与预订服务板块遭遇断崖式下滑。作为互联网医美平台， 新氧介于医疗美容机构与医美终端市场消费者之间， ...

每经AI快讯，1月20日，朗姿股份(002612.SZ)公告称，朗姿股份发布2025年度业绩预告，预计归属于上 市公司股东的净利润为9.00亿元~10.50亿元，比上年同期增长245.25%~302.80%。报告期内，公司处置 若羽臣部分股票并将剩余股权转为交易性金融资产，确认投资收益及公允价值变动损益，导致净利润大 幅上升。 ...

作为医美行业的领军企业，爱美客通过一系列创新实践，既实现了自身的高质量发展，更引领了行业的 转型方向。未来，随着国际化布局的深化与新技术、新产品的持续落地，公司将继续以创新为核心驱动 力，持续辐射产业生态，为健康中国建设与全球医美行业的进步贡献更多力量。 以上实践取得了技术、行业与社会多方面的成果。公司核心产品市场占有率稳居前列，"濡白天使"作为 国家重点研发计划成果，累计产值已突破30亿元；2024年10月，医用含聚乙烯醇凝胶微球的交联透明质 酸钠凝胶（商品名：嗗科拉）获批，进一步丰富了高端产品线。产学研协同显著提升了公司竞争力与行 业整体水平。同时，公司于2025年获中国整形美容协会授予"2025中国医疗美容行业领袖企业奖"，体现 了对其行业引领地位与创新实力的肯定。在近3000亿元规模的中国医美市场中，爱美客带动行业从价格 竞争转向价值竞争，促进了规范化与高质量发展。在社会价值上，公司积极履行责任，2024年捐赠500 万元发起"幸福明天·新美妈妈"公益项目；2025年捐赠100万元驰援香港大埔火灾受灾同胞，践行"科技 向善"，让创新成果惠及民生。 爱美客（300896）是国内最早聚焦生物医用软组织修复 ...

据交易所数据显示， 汉商集团连续两个交易日涨停，晋级2连板。该股今日于9时59分封涨停，成交额 4.16亿元，换手率12.75%。金融界App AI线索挖掘：近期婴童相关政策利好释放，汉商集团布局 辅助 生殖领域，拥有生殖医院牌照及 干细胞研发资质，同时在 医美材料方面有研发突破，相关业务契合市 场对医疗消费领域的关注，多概念共振下引发市场关注。风险提示：连板股波动剧烈，注意追高风险， 理性投资！（注：以上由AI基于交易所等公开数据生成，内容不构成投资建议。） ...

顶端新闻·河南商报评论员 张丽 医美行业的税收规则，迎来了重要调整。2026年1月1日起，《中华人民共和国增值税法》及其实施条例 正式施行，明确营利性美容医疗机构提供的医疗美容服务，需依法缴纳增值税。 这次调整是回归税收公平的重要举措，意在进一步规范医美行业的税收秩序，核心是推动医美行业实现 公平竞争与规范发展。 过去，因税收优惠政策未明确排除营利性美容医疗机构，这类机构实际上一直享受着免税优惠。对医疗 机构免税的初衷，本是保障公众基本医疗需求，带有公益性，只不过营利性美容医疗机构借用政策搭了 个便车。 此次新规明确要求，营利性美容医疗机构不再享受免税政策，厘清了过去的"模糊地带"，既是税收制度 本义的回归，也让行业税收征管更加公平。 政策调整，将加速行业洗牌，推动市场向合规化方向发展。新政落地后，医美行业成本结构将更加透 明，以往部分机构靠虚列成本来掩盖利润等操作可能行不通了。若机构不规范成本核算，将面临税负成 本增加与罚款风险。 顶端新闻·河南商报评论员认为，随着综合税负成本上升，净利润偏低的中小机构或因承受不住资金压 力退出市场。但从长远看，依法纳税、技术领先、服务优质的合规机构，将在公平的税收环境中， ...

部分机构联合金融平台推出"医美贷"，宣称零首付、零利息，实则暗藏高额利率和手续费。消费者术后 不仅要承担还款压力，还可能因逾期还款面临催收困扰。 无医疗资质违规开展医美项目的情况屡见不鲜。一些普通美容院、美甲店等违规开展注射美容、激光治 疗等侵入性项目。此类机构缺乏无菌环境和专业设备，极易引发感染等严重后果。 制造容貌焦虑是商家惯用的营销手段。消费者进店咨询、体验时，商家会通过预先设定好的话术进行洗 脑式营销，放大消费者的容貌焦虑，诱导其购买高价项目。 （来源：中国消费者报） 本报福州讯（林建伟 记者张文章）随着"颜值经济"持续升温，医美行业发展迅速，与此同时，虚假宣 传、低价套路、非法行医等乱象也时有发生。1月16日，福建省厦门市消费者权益保护委员会梳理出医 美领域常见的六大陷阱及避坑指南，提醒消费者留意医美背后暗藏的套路和风险，科学理性消费。 部分商家通过虚假宣传诱导消费者买单，从夸大伪造医生资质、虚构明星案例，到虚假宣传产品使用效 果、手术效果，在宣传造势上无所不用其极，目的就是吸引消费者关注。 低价引流也是常见的消费套路。"199元水光针""299元双眼皮"等低价广告极具吸引力，但消费者到店 后，却被 ...

Group 1 - The company held its 37th meeting of the fifth board of directors on January 16, 2026, to discuss and approve a proposal regarding joint investment with related parties [2][4] - The proposal aims to accelerate the national layout strategy of the company's medical beauty business and establish a long-term incentive and restraint mechanism for key employees [3][8] - The company has been utilizing employee stock ownership platforms to jointly invest in new medical beauty institutions since July 2017, with the full subsidiary, Langzi Medical Management Group Co., Ltd., acting as the general partner [3][8] Group 2 - The board approved the proposal with a unanimous vote, with one related director abstaining from the vote [4][9] - The independent directors held a special meeting and agreed that the pricing and terms of the related transactions are fair and do not harm the interests of the company or its minority shareholders [29][30] - The expected investment amounts for key personnel involved in the employee stock ownership platforms were detailed, with specific figures provided for each individual [10][12][14][15]